{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:32:11Z","timestamp":1767706331617,"version":"3.40.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00259-020-04689-y","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T10:53:53Z","timestamp":1580813633000},"page":"2175-2185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A kinetics-based approach to amyloid PET semi-quantification"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4094-9942","authenticated-orcid":false,"given":"A.","family":"Chincarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Peira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Corosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Assal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Paghera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Savelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U. P.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"4689_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"4689_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"4689_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131:1630\u201345. https:\/\/doi.org\/10.1093\/brain\/awn016.","journal-title":"Brain"},{"key":"4689_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"4689_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [18 F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer\u2019s disease: Specific detection of advanced phases of amyloid-\u03b2 pathology. Alzheimers Dement. 2015;11:975\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.018.","journal-title":"Alzheimers Dement"},{"key":"4689_CR6","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210\u20137.","journal-title":"J Nucl Med"},{"key":"4689_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1212\/WNL.0000000000003126","volume":"87","author":"R Wolz","year":"2016","unstructured":"Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DLG, Alzheimer\u2019s Disease Neuroimaging Initiative. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology. 2016;87:1235\u201341.","journal-title":"Neurology"},{"key":"4689_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496\u2013505.","journal-title":"Semin Ultrasound CT MR"},{"key":"4689_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623\u20138.","journal-title":"J Nucl Med"},{"key":"4689_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2014;1:534\u201343. https:\/\/doi.org\/10.1002\/acn3.81.","journal-title":"Ann Clin Transl Neurol"},{"key":"4689_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","volume":"11","author":"WJ Jagust","year":"2015","unstructured":"Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer\u2019s disease neuroimaging initiative 2 PET core: 2015. Alzheimers Dement. 2015;11:757\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.001.","journal-title":"Alzheimers Dement"},{"key":"4689_CR12","doi-asserted-by":"publisher","first-page":"1\u201315.e1\u20134","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.e1\u20134.","journal-title":"Alzheimers Dement"},{"key":"4689_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3233\/JAD-131979","volume":"43","author":"V Tryputsen","year":"2015","unstructured":"Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N, et al. Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. J Alzheimers Dis. 2015;43:809\u201321.","journal-title":"J Alzheimers Dis"},{"key":"4689_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroimage.2014.11.058","volume":"107","author":"Y Su","year":"2015","unstructured":"Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55\u201364.","journal-title":"Neuroimage"},{"key":"4689_CR15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jalz.2014.09.004","volume":"11","author":"ME Schmidt","year":"2015","unstructured":"Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050\u201368.","journal-title":"Alzheimers Dement"},{"key":"4689_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3233\/JAD-160232","volume":"54","author":"A Chincarini","year":"2016","unstructured":"Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, et al. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis. 2016;54:1437\u201357.","journal-title":"J Alzheimers Dis"},{"key":"4689_CR17","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1007\/s00259-017-3750-0","volume":"44","author":"D Cecchin","year":"2017","unstructured":"Cecchin D, Barthel H, Poggiali D, Cagnin A, Tiepolt S, Zucchetta P, et al. A new integrated dual time-point amyloid PET\/MRI data analysis method. Eur J Nucl Med Mol Imaging. 2017;44:2060\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4689_CR18","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398\u2013407.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4689_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. J Nucl Med. 2013;54:476\u201390. https:\/\/doi.org\/10.2967\/jnumed.113.120618.","journal-title":"J Nucl Med"},{"key":"4689_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med. 2010;51:913\u201320. https:\/\/doi.org\/10.2967\/jnumed.109.069088.","journal-title":"J Nucl Med"},{"key":"4689_CR21","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528\u201347.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4689_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2191-219x-2-11","volume":"2","author":"KB Contractor","year":"2012","unstructured":"Contractor KB, Kenny LM, Coombes CR, Turkheimer FE, Aboagye EO, Rosso L. Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data. EJNMMI Res. 2012;2:11. https:\/\/doi.org\/10.1186\/2191-219x-2-11.","journal-title":"EJNMMI Res"},{"key":"4689_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393\u2013400.","journal-title":"J Nucl Med"},{"key":"4689_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mrm.22002","volume":"62","author":"MJP van Osch","year":"2009","unstructured":"van Osch MJP, Teeuwisse WM, van Walderveen MAA, Hendrikse J, Kies DA, van Buchem MA. Can arterial spin labeling detect white matter perfusion signal? Magn Reson Med. 2009;62:165\u201373.","journal-title":"Magn Reson Med"},{"key":"4689_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1073\/pnas.91.1.33","volume":"91","author":"DA Roberts","year":"1994","unstructured":"Roberts DA, Detre JA, Bolinger L, Insko EK, Leigh JS. Quantitative magnetic resonance imaging of human brain perfusion at 1.5 T using steady-state inversion of arterial water. Proc Natl Acad Sci. 1994;91:33\u20137. https:\/\/doi.org\/10.1073\/pnas.91.1.33.","journal-title":"Proc Natl Acad Sci"},{"key":"4689_CR26","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/mrm.21670","volume":"60","author":"I Asllani","year":"2008","unstructured":"Asllani I, Borogovac A, Brown TR. Regression algorithm correcting for partial volume effects in arterial spin labeling MRI. Magn Reson Med. 2008;60:1362\u201371.","journal-title":"Magn Reson Med"},{"key":"4689_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/1522-2594(200009)44:3<450::aid-mrm16>3.0.co;2-0","volume":"44","author":"FQ Ye","year":"2000","unstructured":"Ye FQ, Berman KF, Ellmore T, Esposito G, van Horn JD, Yang Y, et al. H215O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans. Magn Reson Med. 2000;44:450\u20136. https:\/\/doi.org\/10.1002\/1522-2594(200009)44:3<450::aid-mrm16>3.0.co;2-0.","journal-title":"Magn Reson Med"},{"key":"4689_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/00004647-200008000-00010","volume":"20","author":"I Law","year":"2000","unstructured":"Law I, Iida H, Holm S, Nour S, Rostrup E, Svarer C, et al. Quantitation of regional cerebral blood flow corrected for partial volume effect using O-15 water and PET: II. Normal values and gray matter blood flow response to visual activation. J Cereb Blood Flow Metab. 2000;20:1252\u201363.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4689_CR29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/brain\/awh131","volume":"127","author":"S Momjian","year":"2004","unstructured":"Momjian S, Owler BK, Czosnyka Z, Czosnyka M, Pena A, Pickard JD. Pattern of white matter regional cerebral blood flow and autoregulation in normal pressure hydrocephalus. Brain. 2004;127:965\u201372.","journal-title":"Brain"},{"key":"4689_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.WCB.0000093326.88757.49","volume":"24","author":"BK Owler","year":"2004","unstructured":"Owler BK, Momjian S, Czosnyka Z, Czosnyka M, P\u00e9na A, Harris NG, et al. Normal pressure hydrocephalus and cerebral blood flow: a PET study of baseline values. J Cereb Blood Flow Metab. 2004;24:17\u201323.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4689_CR31","doi-asserted-by":"publisher","unstructured":"Leinonen V, Rinne JO, Wong DF, Wolk DA, Trojanowski JQ, Sherwin PF, et al. Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid \u03b2 using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun. 2014;2. https:\/\/doi.org\/10.1186\/2051-5960-2-46.","DOI":"10.1186\/2051-5960-2-46"},{"key":"4689_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70\u20137. https:\/\/doi.org\/10.2967\/jnumed.112.109009.","journal-title":"J Nucl Med"},{"key":"4689_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","volume":"79","author":"PM Doraiswamy","year":"2012","unstructured":"Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-\u03b2 assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636\u201344.","journal-title":"Neurology"},{"key":"4689_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid- PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.149732.","journal-title":"J Nucl Med"},{"key":"4689_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal -amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567\u201374. https:\/\/doi.org\/10.2967\/jnumed.114.148981.","journal-title":"J Nucl Med"},{"key":"4689_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neuroimage.2014.11.055","volume":"108","author":"M Brendel","year":"2015","unstructured":"Brendel M, H\u00f6genauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450\u20139.","journal-title":"Neuroimage"},{"key":"4689_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jalz.2017.02.009","volume":"13","author":"AS Fleisher","year":"2017","unstructured":"Fleisher AS, Joshi AD, Sundell KL, Chen Y-F, Kollack-Walker S, Lu M, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement. 2017;13:1117\u201324.","journal-title":"Alzheimers Dement"},{"key":"4689_CR38","doi-asserted-by":"publisher","first-page":"e0152082","DOI":"10.1371\/journal.pone.0152082","volume":"11","author":"Y Su","year":"2016","unstructured":"Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer\u2019s disease: results from the DIAN study group. PLoS One. 2016;11:e0152082.","journal-title":"PLoS One"},{"key":"4689_CR39","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1073\/pnas.200033797","volume":"97","author":"B Fischl","year":"2000","unstructured":"Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97:11050\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 2","key":"4689_CR40","first-page":"425","volume":"188","author":"S Sisodiya","year":"1996","unstructured":"Sisodiya S, Free S, Fish D, Shorvon S. MRI-based surface area estimates in the normal adult human brain: evidence for structural organisation. J Anat. 1996;188(Pt 2):425\u201338.","journal-title":"J Anat"},{"key":"4689_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/1097-0193(200009)11:1<12::aid-hbm20>3.0.co;2-k","volume":"11","author":"SE Jones","year":"2000","unstructured":"Jones SE, Buchbinder BR, Aharon I. Three-dimensional mapping of cortical thickness using Laplace\u2019s equation. Hum Brain Mapp. 2000;11:12\u201332. https:\/\/doi.org\/10.1002\/1097-0193(200009)11:1<12::aid-hbm20>3.0.co;2-k.","journal-title":"Hum Brain Mapp"},{"key":"4689_CR42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.neuroimage.2008.01.027","volume":"40","author":"C Hutton","year":"2008","unstructured":"Hutton C, De Vita E, Ashburner J, Deichmann R, Turner R. Voxel-based cortical thickness measurements in MRI. NeuroImage. 2008;40:1701\u201310. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.01.027.","journal-title":"NeuroImage"},{"key":"4689_CR43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/cercor\/bhh200","volume":"15","author":"JP Lerch","year":"2005","unstructured":"Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer\u2019s disease identified by computational neuroanatomy. Cereb Cortex. 2005;15:995\u20131001.","journal-title":"Cereb Cortex"},{"key":"4689_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","volume":"14","author":"S Daerr","year":"2017","unstructured":"Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, et al. Evaluation of early-phase [ 18 F]-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical. 2017;14:77\u201386. https:\/\/doi.org\/10.1016\/j.nicl.2016.10.005.","journal-title":"NeuroImage: Clinical"},{"key":"4689_CR45","doi-asserted-by":"publisher","first-page":"P763","DOI":"10.1016\/j.jalz.2017.06.1018","volume":"13","author":"J Ottoy","year":"2017","unstructured":"Ottoy J, Miedema M, De Puydt C, Verhaeghe J, Deleye S, Engelborghs S, et al. Early frame 18F-AV45 and 18F-FDG-PET as proxies of CBF: comparison to 15O-H2O PET data. Alzheimers Dement. 2017;13:P763\u20134. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.1018.","journal-title":"Alzheimers Dement"},{"key":"4689_CR46","doi-asserted-by":"publisher","unstructured":"Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011. https:\/\/doi.org\/10.2967\/jnumed.110.082057.","DOI":"10.2967\/jnumed.110.082057"},{"key":"4689_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.114.152405","volume":"56","author":"YJ Chen","year":"2015","unstructured":"Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, et al. Relative 11C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-PiB PET. J Nucl Med. 2015;56:1199\u2013205.","journal-title":"J Nucl Med"},{"key":"4689_CR48","doi-asserted-by":"publisher","first-page":"101846","DOI":"10.1016\/j.nicl.2019.101846","volume":"23","author":"A Chincarini","year":"2019","unstructured":"Chincarini A, Peira E, Morbelli S, Pardini M, Bauckneht M, Arbizu J, et al. Semi-quantification and grading of amyloid PET: a project of the European Alzheimer\u2019s Disease Consortium (EADC). NeuroImage: Clinical. 2019;23:101846. https:\/\/doi.org\/10.1016\/j.nicl.2019.101846.","journal-title":"NeuroImage: Clinical"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04689-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:38:11Z","timestamp":1611448691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4689"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04689-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scans were acquired in the clinical setting for diagnostic purposes. All subjects (or their legal representative, if demented) were informed that their scans would have been used for research purposes and gave their written consent. All procedures performed were in accordance with the ethical standards of each local institutional Ethics Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The supervising ethics committee for this study is the CER (Comitato Etico della Regione Liguria), based in Genoa, Italy. Ethics Committees approvals included the transfer of imaging data, all anonymized brain amyloid PET were collected from the centers in DICOM format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Quality of images was checked by an experienced Nuclear Medicine Physician (S.M.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"In the past years, Dr. Nobili received fees from Eli-Lilly & Co for giving teaching course on visual reading of [<sup>18<\/sup>F]Florbetapir, and from Bayer Pharma for participation in an advisory board on [<sup>18<\/sup>F]Florbetaben.Dr. Pardini receives research support from Novartis and Nutricia and received personal fees from Novartis, Merck, Roche. Dr. Pardini is partly supported by a Curiosity-driven grant from the University of Genoa.All other authors disclose no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}